GeoVax Labs (NASDAQ:GOVX) Announces Earnings Results, Beats Estimates By $1.19 EPS

GeoVax Labs (NASDAQ:GOVX) issued its earnings results on Monday. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19, FiscalAI reports.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $0.76 on Tuesday. The company’s 50 day simple moving average is $1.52 and its two-hundred day simple moving average is $1.83. GeoVax Labs has a 1 year low of $0.69 and a 1 year high of $20.62. The stock has a market capitalization of $2.64 million, a PE ratio of -0.04 and a beta of 3.68.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GOVX. Jane Street Group LLC bought a new stake in GeoVax Labs during the first quarter valued at $27,000. HRT Financial LP purchased a new stake in shares of GeoVax Labs in the 4th quarter valued at about $31,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs during the 4th quarter valued at about $104,000. Finally, Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at about $253,000. Institutional investors own 6.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.